VANCOUVER, July 9, 2012 /PRNewswire/ - Anavex Life Sciences Corp. ("Anavex") (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company's lead compound for Alzheimer's disease currently in human clinical trials, will be presented in a poster session at the 2012 Alzheimer's Association International Conference (AAIC) in Vancouver, BC, Canada.
The ANAVEX 2-73 poster will be presented by Tangui Maurice, PhD, CNRS Research Director, Team II Endogenous Neuroprotection in Neurodegenerative Diseases INSERM, University of Montpellier. Presentation details are as follows:
|Date:||Monday, July 16, 2012|
|Time:||1 p.m. to 3:30 p.m.|
|Title:||Neuroprotective efficacy of ANAVEX 2-73, a novel tetrahydrofuran derivative targeting the sigma-1 chaperone protein, in a mouse model of Alzheimer's disease: Analyses of administration schedules and combination studies with donepezil and memantine|
Note to editors: Pursuant to AAIC policy, the abstract for this poster presentation cannot be disclosed until the formal presentation has been made.
Any parties interested in meeting with the Anavex team at AAIC may contact the company's communications team at +1 (416) 489-0092 or firstname.lastname@example.org.
AAIC 2012 takes place Saturday, July 14 to Thursday, July 19, 2012 in Vancouver. It is the world's premiere forum for reporting and discussion of groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders. Additional information about the conference is available at http://www.alz.org/aaic/.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (www.anavex.com) is a pharmaceutical company engaged in the development of novel drug candidates. Anavex utilizes its proprietary SIGMACEPTOR™ Platform to develop drug candidates targeting specific clinical indications. Lead compound ANAVEX 2-73, developed to treat Alzheimer's through disease modification, is in human clinical trials. A Phase 1 single ascending dose study of ANAVEX 2-73 was successfully completed in Germany in 2011. Studies indicate that ANAVEX 2-73 demonstrates anti-amnesic and neuroprotective properties, and that it is well tolerated in doses up to 55mg. The company is preparing to embark on a multiple ascending dose clinical trial of ANAVEX 2-73 in 2012. Anavex is a publicly traded corporation quoted as AVXL.
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Forward-looking statements in this press release include that Dr. Maurice will make a presentation at AAIC in Vancouver; that the presentation will pertain to Anavex and ANAVEX 2-73, its lead drug candidate for Alzheimer's disease; that we are moving forward with clinical trials; and that data from a prior trial indicates that the compound is well tolerated. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery and development, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to pass clinical trials so as to move on to the next phase, our ability to finance development or satisfy the rigorous regulatory requirements for new drugs, our ability to attract and retain quality personnel, and that despite positive results, our competitors may offer better or cheaper alternatives. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
Anavex Life Sciences Corp.
Research & Business Development
SOURCE Anavex Life Sciences Corp.